EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing Treatment in Pediatric Multiple Sclerosis: The Promise of B-Cell-Targeting Therapies

Charalampos Skarlis iD, Maria Kotsari, Maria Anagnostouli iD

International Journal of Molecular Sciences · 22.06.2025 · 26 (13) · 5989

DOI: 10.3390/ijms26135989 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.06.2025. Verfasst von Charalampos Skarlis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Immunogenetics Laboratory, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Aeginition Uni…. Hauptthemen laut MEDLINE: B-Lymphocytes, Multiple Sclerosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric-onset multiple sclerosis (POMS) is a rare yet increasingly recognized demyelinating disease of the central nervous system, characterized by a highly inflammatory disease course and an elevated relapse rate compared to adult-onset MS (AOMS). Given the unique immunopathogenesis of POMS, recent therapeutic strategies have shifted toward early initiation of high-efficacy disease-modifying therapies (DMTs) to minimize irreversible neurological damage. Among these, B-cell-targeting therapies, particularly anti-CD20 monoclonal antibodies, have shown efficacy in adult MS and are emerging as promising candidates for POMS treatment. The present review summarizes the current knowledge of the role of B-cells in POMS pathophysiology and evaluates the therapeutic potential of anti-CD-20 agents. It also highlights ongoing clinical trials and future perspectives, including novel B-cell-directed approaches such as anti-CD19 therapies, Bruton’s tyrosine kinase (BTK) inhibitors, and BAFF-targeting agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-LymphocytesMultiple SclerosisHumansChildMolecular Targeted TherapyAntigens, CD20Antibodies, MonoclonalB-Cell Activating Factor

Stichwörter der Autor:innen

AlemtuzumabB-cellsBTKisOcrelizumabOfatumumbRituximabpediatric-onset multiple sclerosisrare demyelinating CNS diseases

Substanzen

Antigens, CD20Antibodies, MonoclonalB-Cell Activating Factor

Autor:innen und Institutionen

  • Research Immunogenetics Laboratory, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Aeginition University Hospital, Vas. Sofias 72-74, 11528 Athens, Greece.
  • Multiple Sclerosis and Demyelinating Diseases Unit, Center of Expertise for Rare Demyelinating and Autoimmune Diseases of CNS, First Department of Neurology, School of Medicine, National and Kapodistrian University of A…

ORCID-Profile: Charalampos Skarlis, Maria Anagnostouli

Zitieren

APA

Skarlis, C., Kotsari, M., & Anagnostouli, M. (2025). Advancing Treatment in Pediatric Multiple Sclerosis: The Promise of B-Cell-Targeting Therapies. International Journal of Molecular Sciences, 26(13), 5989. https://doi.org/10.3390/ijms26135989

Vancouver

Skarlis C, Kotsari M, Anagnostouli M. Advancing Treatment in Pediatric Multiple Sclerosis: The Promise of B-Cell-Targeting Therapies. International Journal of Molecular Sciences. 2025;26(13):5989. doi:10.3390/ijms26135989

BibTeX
@article{Skarlis2025,
  author = {Skarlis, Charalampos and Kotsari, Maria and Anagnostouli, Maria},
  title = {Advancing Treatment in Pediatric Multiple Sclerosis: The Promise of B-Cell-Targeting Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {13},
  pages = {5989},
  doi = {10.3390/ijms26135989}
}
Kostenlos starten →